N Rodríguez de Dios1,2,3, X Sanz4,5,6, P Foro4,5,6, I Membrive4,5, A Reig4,5, A Ortiz4,5, R Jiménez4,5, M Algara4,5,6. 1. Department of Radiation Oncology, Hospital de la Esperanza, Parc de Salut Mar, c/San José de la Montaña, 12, 08024, Barcelona, Spain. nrodriguez@parcdesalutmar.cat. 2. Hospital del Mar Medical Research Institute (IMIM), Doctor Aiguader 88, 08003, Barcelona, Spain. nrodriguez@parcdesalutmar.cat. 3. Pompeu Fabra University, Doctor Aiguader 80, 08003, Barcelona, Spain. nrodriguez@parcdesalutmar.cat. 4. Department of Radiation Oncology, Hospital de la Esperanza, Parc de Salut Mar, c/San José de la Montaña, 12, 08024, Barcelona, Spain. 5. Hospital del Mar Medical Research Institute (IMIM), Doctor Aiguader 88, 08003, Barcelona, Spain. 6. Pompeu Fabra University, Doctor Aiguader 80, 08003, Barcelona, Spain.
Abstract
PURPOSE: To report interim results from a single-institution study conducted to assess accelerated hypofractionated radiotherapy (AHRT) delivered with 3D conformal radiotherapy in two groups of patients with non-small cell lung cancer: (1) patients with early stage disease unable to tolerate surgery and ineligible for stereotactic body radiation therapy, and (2) patients with locally advanced disease unsuitable for concurrent chemoradiotherapy. METHODS/PATIENTS: A total of 83 patients (51 stage I-II, 32 stage III) were included. Radiotherapy targets included the primary tumor and positive mediastinal areas identified on the pre-treatment PET-CT. Mean age was 77.8 ± 7.8 years. ECOG performance status (PS) was ≥2 in 50.6 % of cases. Radiotherapy was delivered in daily fractions of 2.75 Gy to a total dose of 66 Gy (BED10 84 Gy). Acute and late toxicities were evaluated according to NCI CTC criteria. RESULTS: At a median follow-up of 42 months, median overall survival (OS) and cause-specific survival (CSS) were 23 and 36 months, respectively. On the multivariate analysis, PS [HR 4.14, p = 0.0001)], stage [HR 2.51, p = 0.005)], and maximum standardized uptake values (SUVmax) [HR 1.04, p = 0.04)] were independent risk factors for OS. PS [HR 5.2, p = 0.0001)] and stage [HR 6.3, p = 0.0001)] were also associated with CSS. No cases of severe acute or late treatment-related toxicities were observed. CONCLUSIONS: OS and CSS rates in patients treated with AHRT for stage I-II and stage III NSCLC were good. Treatment was well tolerated with no grade three or higher treatment-related toxicity. PS, stage, and SUV max were predictive for OS and CSS.
PURPOSE: To report interim results from a single-institution study conducted to assess accelerated hypofractionated radiotherapy (AHRT) delivered with 3D conformal radiotherapy in two groups of patients with non-small cell lung cancer: (1) patients with early stage disease unable to tolerate surgery and ineligible for stereotactic body radiation therapy, and (2) patients with locally advanced disease unsuitable for concurrent chemoradiotherapy. METHODS/PATIENTS: A total of 83 patients (51 stage I-II, 32 stage III) were included. Radiotherapy targets included the primary tumor and positive mediastinal areas identified on the pre-treatment PET-CT. Mean age was 77.8 ± 7.8 years. ECOG performance status (PS) was ≥2 in 50.6 % of cases. Radiotherapy was delivered in daily fractions of 2.75 Gy to a total dose of 66 Gy (BED10 84 Gy). Acute and late toxicities were evaluated according to NCI CTC criteria. RESULTS: At a median follow-up of 42 months, median overall survival (OS) and cause-specific survival (CSS) were 23 and 36 months, respectively. On the multivariate analysis, PS [HR 4.14, p = 0.0001)], stage [HR 2.51, p = 0.005)], and maximum standardized uptake values (SUVmax) [HR 1.04, p = 0.04)] were independent risk factors for OS. PS [HR 5.2, p = 0.0001)] and stage [HR 6.3, p = 0.0001)] were also associated with CSS. No cases of severe acute or late treatment-related toxicities were observed. CONCLUSIONS:OS and CSS rates in patients treated with AHRT for stage I-II and stage III NSCLC were good. Treatment was well tolerated with no grade three or higher treatment-related toxicity. PS, stage, and SUV max were predictive for OS and CSS.
Authors: Kenneth D Westover; Billy W Loo; David E Gerber; Puneeth Iyengar; Hak Choy; Maximilian Diehn; Randy Hughes; Joan Schiller; Jonathan Dowell; Zabi Wardak; David Sher; Alana Christie; Xian-Jin Xie; Irma Corona; Akanksha Sharma; Margaret E Wadsworth; Robert Timmerman Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-09 Impact factor: 7.038
Authors: Frank Zimmermann; Jörn Wulf; Ingmar Lax; Yasushi Nagata; Robert D Timmerman; Igor Stojkovski; Branislav Jeremic Journal: Front Radiat Ther Oncol Date: 2009-11-24
Authors: Jeffrey A Bogart; Lydia Hodgson; Stephen L Seagren; A William Blackstock; Xiaofei Wang; Robert Lenox; Andrew T Turrisi; John Reilly; Ajeet Gajra; Everett E Vokes; Mark R Green Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: John T Lucas; Jeffrey G Kuremsky; Mike Soike; William W Hinson; William T Kearns; Carnell J Hampton; A William Blackstock; James Urbanic Journal: Lung Cancer Date: 2014-04-28 Impact factor: 6.081
Authors: Anna Merlotti; Alessio Bruni; Paolo Borghetti; Sara Ramella; Vieri Scotti; Marco Trovò; Rita Chiari; Frank Lohr; Umberto Ricardi; Emilio Bria; Giovanni L Pappagallo; Rolando M D'Angelillo; Stefano Arcangeli Journal: Radiol Med Date: 2021-05-05 Impact factor: 3.469
Authors: Núria Rodríguez De Dios; Arturo Navarro-Martin; Cristina Cigarral; Rodolfo Chicas-Sett; Rafael García; Virginia Garcia; Jose Antonio Gonzalez; Susana Gonzalo; Mauricio Murcia-Mejía; Rogelio Robaina; Amalia Sotoca; Carmen Vallejo; German Valtueña; Felipe Couñago Journal: World J Clin Oncol Date: 2022-04-24